Fundamental Data for ANSV

ANESIVA IN(NSDQ:ANSV)

Corgentech Inc is a biopharmaceutical company focused on the discovery, development and commercialization of a new class of therapeutics called transcription factor decoys, or TF Decoys, for the treatment of cardiovascular disease, inflammatory disease, and cancer.

# Employees: 100

Address: 650 Gateway Boulevard,South San Francisco,CA,USA

Phone: 650 624-9600

Fax: 650 624-7540

Website: www.anesiva.com

Email: investors@anesiva.com

Sector: Medical

Industry: MED-BIOMED/GENE

Executive Officers

Rodney A. Ferguson Ph.D. (Chairman)

John P. McLaughlin (C.E.O.; Dir.)

John X. Regan (Sr. V.P.; Operations)

Nancy E. Donahue (Sr. V.P. Mark.)

Jean-Fr??d??ric Viret Ph. (. V.P.; C.F.O.,)

Dividend

Ex-Dividend Date: N/A

Annual Dividend: N/A

Current Dividend Yield: N/A

Dividend Paid (3 months): N/A

Indicated Dividend: N/A

Earnings

Last Earnings Date: 6/30/2008

Next Earnings Date(Expected): 11/26/2009

Mean EPS (Next Qtr): ($0.01)

Mean EPS (Year): ($0.01)

Mean Estimate(Long Term): ($0.01)

P/E Ratio(Based on EPS estimate): -0.010

Number of Estimates: 0

Shares Performance

Period	ANSV	Compare to S&P
YTD	-64.49 %	-70.61 %
4 Weeks	-19.56 %	-23.64 %
12 Weeks	-55.36 %	-58.43 %

Shares Information

Analyst Coverage: N

Avg Volume: 512549

Shares Outstanding: 40M

Market Cap: $0.01B

52 Week High: $0.93

52 Week Low: $0.07

P/E Ratio: -0.010

PEG Ratio: -0.010

Split: On 12/16/2005 ANSV split by factor of 0.250

Earnings Performance

EPS Growth in Last Quarter: -5.56 %

EPS Growth in Last Year: 1.72 %

Sales Growth in Last Quarter: -99.67 %

Sales Growth in Last Quarter: -98.00 %

Financials

Qtr Book Value: ($0.01)

Cash Flow/Share: ($0.01)

Change in Payout Ratio: -0.010

Price/Sales: -0.010